Reuters: Health
GlaxoSmithKline and AstraZeneca both reported trial results that will likely make their competing drugs available to a wider group of ovarian cancer patients, possibly helping GSK catch its rival in a highly contested drug class.
Separate GSK, AstraZeneca trial results may widen ovarian cancer drug use
Separate GSK, AstraZeneca trial results may widen ovarian cancer drug use
Reuters: Health
GlaxoSmithKline and AstraZeneca both reported trial results that will likely make their competing drugs available to a wider group of ovarian cancer patients, possibly helping GSK catch its rival in a highly contested drug class.
Reuters: Health
GlaxoSmithKline and AstraZeneca both reported trial results that will likely make their competing drugs available to a wider group of ovarian cancer patients, possibly helping GSK catch its rival in a highly contested drug class.
Subscribe to:
Post Comments (Atom)
Popular Posts
|
No comments:
Post a Comment